ENDOXAN 1000 mg
Sponsors
French Innovative Leukemia Organization, Cellectis, Lysarc, Institut Curie, Institut Paoli Calmettes
Conditions
Breast cancerPatients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapyPatients with previously untreated Richter’s syndrome (RS)Relapsed or refractory B-cell Acute Lymphoblastic
LeukemiaRelapsed or Refractory Marginal Zone LymphomaRelapsed or refractory B-cell Non-Hodgkin lymphomaRetinoblastomadefined as the transformation of chronic lymphocytic leukemia (CLL) into high-grade lymphoma of diffuse large B-cell lymphoma (DLBCL) histology.
Phase 1
Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
RecruitingCTIS2022-501607-27-00
Start: 2026-01-06Target: 48Updated: 2026-01-08
Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Active, not recruitingCTIS2022-502305-15-00
Start: 2025-11-26Target: 40Updated: 2025-11-26
Phase 2
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
RecruitingCTIS2022-501554-11-00
Start: 2024-03-21Target: 40Updated: 2025-12-24
RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated
Active, not recruitingCTIS2024-514844-10-00
Start: 2010-03-18Target: 195Updated: 2025-07-01
PELICAN-IPC 2015-016 A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen in HER2-negative inflammatory Breast Cancer
Not yet recruitingCTIS2024-514899-41-00
Target: 72Updated: 2024-10-31